Bonnet, Céline
Pellerin, David
Roth, Virginie
Clément, Guillemette
Wandzel, Marion
Lambert, Laëtitia
Frismand, Solène
Douarinou, Marian
Grosset, Anais
Bekkour, Ines
Weber, Frédéric
Girardier, Florent
Robin, Clément
Cacciatore, Stéphanie
Bronner, Myriam
Pourié, Carine
Dreumont, Natacha
Puisieux, Salomé
Iruzubieta, Pablo
Dicaire, Marie-Josée
Evoy, François
Rioux, Marie-France
Hocquel, Armand
La Piana, Roberta
Synofzik, Matthis
Houlden, Henry
Danzi, Matt C.
Zuchner, Stephan
Brais, Bernard
Renaud, Mathilde
Funding for this research was provided by:
Fondation Groupe Monaco
Montreal General Hospital Foundation (PT79418)
Article History
Received: 31 January 2023
Accepted: 7 June 2023
First Online: 15 June 2023
Competing interests
: Matthis Synofzik has received consultancy honoraria from Janssen, Ionis, Orphazyme, Servier, Reata, GenOrph, and AviadoBio, all unrelated to the present manuscript. Stephan Zuchner is consultant on drug targets for Aeglea BioTherapeutics and consultant on clinical trial design for Applied Therapeutics, all of them unrelated to the work in the present manuscript. Other authors have no relevant financial interests to disclose.